Abstract
Schizophrenia is a chronic and debilitating brain disorder. It is associated with increased mortality, primarily due to elevated cardio-metabolic risk. Affected patients have higher rates of obesity, metabolic syndrome and diabetes [1]. Intrinsic factors contributing to this increased risk include a shared underlying pathophysiology between schizophrenia and diabetes mellitus involving stress, inflammation and genetics. Extrinsic contributing factors include diet, lifestyle, health care access, low socioeconomic status and overburden of traditional diabetes risk factors. Antipsychotics are associated with an increased risk of obesity, metabolic syndrome and diabetes mellitus [1]. Appetite-regulating hormones, pharmacodynamics and alterations in glucose metabolism may underlie the negative effect of these medications. Reduction in diabetes risk is achieved by mitigating traditional risk factors. Non-pharmacologic and pharmacologic approaches to cardio-metabolic risk reduction may be helpful in these patients.
Keywords: Antipsychotics, diabetes mellitus, metabolic syndrome, obesity, schizophrenia.
Current Diabetes Reviews
Title:The Complex Inter-Relationship Between Diabetes and Schizophrenia
Volume: 13 Issue: 3
Author(s): Jeffrey Rado*
Affiliation:
- Department of Psychiatry and General Internal Medicine, Northwestern University, Chicago, IL,United States
Keywords: Antipsychotics, diabetes mellitus, metabolic syndrome, obesity, schizophrenia.
Abstract: Schizophrenia is a chronic and debilitating brain disorder. It is associated with increased mortality, primarily due to elevated cardio-metabolic risk. Affected patients have higher rates of obesity, metabolic syndrome and diabetes [1]. Intrinsic factors contributing to this increased risk include a shared underlying pathophysiology between schizophrenia and diabetes mellitus involving stress, inflammation and genetics. Extrinsic contributing factors include diet, lifestyle, health care access, low socioeconomic status and overburden of traditional diabetes risk factors. Antipsychotics are associated with an increased risk of obesity, metabolic syndrome and diabetes mellitus [1]. Appetite-regulating hormones, pharmacodynamics and alterations in glucose metabolism may underlie the negative effect of these medications. Reduction in diabetes risk is achieved by mitigating traditional risk factors. Non-pharmacologic and pharmacologic approaches to cardio-metabolic risk reduction may be helpful in these patients.
Export Options
About this article
Cite this article as:
Rado Jeffrey*, The Complex Inter-Relationship Between Diabetes and Schizophrenia, Current Diabetes Reviews 2017; 13 (3) . https://dx.doi.org/10.2174/1573399812666161220144740
DOI https://dx.doi.org/10.2174/1573399812666161220144740 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets The Role of Vascular Endothelial Growth Factor Gene as the Genetic Marker of Atherothrombotic Disorders and in the Gene Therapy of Coronary Artery Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design A Systematic Review on Anti-diabetic Properties of Chalcones
Current Medicinal Chemistry Pancreatic β-Cells and Type 2 Diabetes Development
Current Diabetes Reviews By Passing Microbial Resistance: Xylitol Controls Microorganisms Growth by Means of Its Anti-Adherence Property
Current Pharmaceutical Biotechnology Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Editorial [Hot Topic: Novel Peptides and Proteins in Diabetes Mellitus (Guest Editors: Po Sing Leung and Marc de Gasparo)]
Current Protein & Peptide Science Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism
Current HIV Research Role of Polyphenols in Diet and Nutrition-An Updated Review
Current Nutrition & Food Science Role of PI3K/AKT, cPLA2 and ERK1/2 Signaling Pathways in Insulin Regulation of Vascular Smooth Muscle Cells Proliferation
Cardiovascular & Hematological Disorders-Drug Targets Combinatorial Protein Biochemistry for Therapeutics and Proteomics
Current Pharmaceutical Biotechnology Glucagon and Glucagon-like Peptide-1 Receptors: Promising Therapeutic Targets for an Effective Management of Diabetes Mellitus
Current Pharmaceutical Design Resistin: A Promising Therapeutic Target for the Management of Type 2 Diabetes Mellitus?
Drug Design Reviews - Online (Discontinued) Diagnostic Approach to Mitochondrial Disorders: the Need for a Reliable Biomarker
Current Molecular Medicine Combination Therapy with Chinese Medicine and ACEI/ARB for the Management of Diabetic Nephropathy: The Promise in Research Fragments
Current Vascular Pharmacology